Next-IO™ Anti-CD96 Monoclonal Antibody Program

As a thriving CRO company, Creative Biolabs has the initiative to acquire, develop and commercialize Next-IO™ programs with a goal to treat cancers. Creative Biolabs is now proposing a comprehensive set of Next-IO™ programs to develop promising mAb candidates with the help of partners. We have expertise and talented team in place to assist every step of the way. This Next-IO™ Anti-CD96 Monoclonal Antibody Program aims to develop a therapeutic monoclonal antibody against CD96.

Targeting Immune Checkpoints of NK Cell for Immunotherapy

As a key innate immune modulator, natural killer (NK) cell can recognize transformed cells and is critical to cancer response. In recent years, research on immune checkpoint inhibitors has revolutionized so much that enhancing cytotoxic immune activities become a possibility. Scientists already identified some potent checkpoints for NK cell activation. This program focuses on the immune checkpoint of NK cell - CD96, i.e. the receptor of CD155/PVR expressed on target cells (see Fig.1).

Interaction between CD96 immune receptor with nectin-like protein-5, CD155. Fig.1 Interaction between CD96 immune receptor with nectin-like protein-5, CD155. (Deuss, 2019)

Mechanism of Action

CD96, also known as TACTILE, was originally identified as an Ig superfamily receptor, but now is thought to play a key inhibitory role in immune functions. CD96 is expressed on both NK cells and T cells, and it can transduce inhibitory signals through interaction with CD155 expressed on target cells. Studies have demonstrated that tumor progression is inhibited when blocking anti-CD96 antibody or CD96 knockout. This inspires us to develop this anti-CD96 mAb program to explore promising cancer therapy.

The signaling pathway of CD96. Fig.2 The signaling pathway of CD96. (Blake, 2016)

Our Anti-CD96 Antibody Program

With extensive experience in the discovery and development of therapeutic antibodies, our scientists are able to explore strategic collaborations with our partners together. We are dedicated to promoting the program to the pre-IND stage in a timely manner. Here are the key features of the program.

Other than monoclonal antibody development, if you are interested in combination strategies, or other antibody modalities, such as a bispecific antibody, etc., please feel free to reach out to our scientists for further assistance.

Checkpoint inhibitors that ‘release’ NK cell functions, such as anti-CD96 mAb. Fig.3 Checkpoint inhibitors that ‘release’ NK cell functions, such as anti-CD96 mAb. (Guillerey, 2016)

Published Data

From the data, we learn that the CD96 shows to be a potential target to treat cancer, and blocking CD96 is a promising immunotherapeutic approach to inhibit tumor metastases and improve survival rate.

Program Planning and Management

We have extensive experience in performing comprehensive program developments and effective problem-solving. For our Next-IO™ programs, we are committed to promoting the program to the pre-IND stage within about 1.5 years. The accurate timeline will be determined on a case-by-case basis. Here is a draft timeline for your glance.

Anti-CD96 Monoclonal Antibody Program

Collaboration

Creative Biolabs is a trusted and reliable partner, who is dedicated to achieving milestones with our partners. We are now inviting potential clients to co-develop this novel mAb program against CD96. With the experience of decades of successful antibody discovery and development, our experts can achieve strategic collaborations between two parties.

If you are interested in this program, please feel free to contact us to learn how we can collaborate. Looking forward to hearing from you.

References

For Research Use Only | Not For Clinical Use

Online Inquiry
Copyright © 2024 Creative Biolabs. All Rights Reserved.